ALYREF and hydrops fetalis: Finally, validation of these findings in prospective and multicenter ADHF-rEF cohorts remains necessary to confirm whether the additive prognostic performance observed for EASIX in our HF population extends to broader health-care settings and mixed-phenotype acute HF populations.